Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs State Street SPDR S&P Biotech ETF — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 107× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MSTZ | XBI | |
|---|---|---|
Market Cap | $94.46M | $10.11B |
Volume | 104,717,733 | 12,903,266 |
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $27.92 | $169.55 |
52-Week Low | $2.29 | $104.99 |
Typical Hold Time | 8 Days | 38 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $2.62, down 1.5% today, with technical indicators showing a bearish bias as moving averages signal selling pressure while oscillators remain neutral. The stock faces resistance at $3 with support at $2, indicating a tight trading range. Recent ETF coverage highlights its inclusion in leveraged fund discussions, though specific company fundamentals remain undisclosed in available data.
The outlook for MSTZ hinges on upcoming financial disclosures to clarify valuation metrics like P/E and profitability. Key risks include limited public financial data and market volatility. Investors await earnings reports to assess growth potential amid current technical weakness.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
